{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T02:47:20Z","timestamp":1770346040178,"version":"3.49.0"},"reference-count":82,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The beneficial effects of statins, other than their hypocholesterolemia role, have been\nwell documented, however, their use as an adjuvant drug with other antiseizure drugs, in the treatment of epilepsy\nis poorly understood.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study aimed to investigate the symbiotic effect of ATOR along with either lacosamide (LACO) or\nlevetiracetam (LEVE) on experimentally induced epilepsy (Maximal electro-shock-MES or pentylenetetrazol-\nPTZ) in mice models.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Conventional elevated-maze (EPM) and rotarod methods were performed to observe the behavioral\neffects.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>In both the animal models, we found that co-administration of ATOR along with LACO showed a significant\nreduction in hind-limb extension (HLE) and clonic convulsion (CC) responses, respectively, but not in the\nATOR+LEVE treated group. Intriguingly, comparable Straub tail response and myoclonic convulsion as the diazepam\n(DIA) group were observed only in the ATOR+LACO treated group. Moreover, a significant muscle-grip\nstrength was observed in both groups. Also, pharmacokinetic analysis has indicated that the mean plasma concentration\nof ATOR peaked at 2nd hr in the presence of LACO but marginally peaked in the presence of LEVE. An Insilico\nstudy has revealed that ATOR has a higher binding affinity toward neuronal sodium channels.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This study has demonstrated that the plasma concentration of ATOR was potentiated in the presence\nof LACO, but not in the presence of LEVE and it has provided significant protection against both the electro and\nchemo-convulsive models in mice. This could be due to the symbiotic pharmacokinetic interplay of ATOR with\nLACO, and possibly, this interplay may interfere with sodium channel conductance.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113892002253895231020100743","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T07:33:33Z","timestamp":1699256013000},"page":"645-655","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Differential Pharmacokinetic Interplay of Atorvastatin on Lacosamide and\nLevetiracetam on Experimental Convulsions in Mice"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6367-0365","authenticated-orcid":true,"given":"Jayaraman","family":"Rajangam","sequence":"first","affiliation":[{"name":"Shri Venkateshwara College of Pharmacy, Ariyur, Pondicherry, 605102, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun Prasath","family":"Lakshmanan","sequence":"additional","affiliation":[{"name":"Sidra Medicine, Research Department, P.O.Box\n26999, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2041-1849","authenticated-orcid":true,"given":"Narahari N.","family":"Palei","sequence":"additional","affiliation":[{"name":"Shri Venkateshwara College of Pharmacy, Ariyur, Pondicherry, 605102, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthikeyan","family":"Elumalai","sequence":"additional","affiliation":[{"name":"Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences University, Chennai,\n602105, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muddukrishnaiah","family":"Kotakonda","sequence":"additional","affiliation":[{"name":"Faculty of Technology, Anna University, Chennai, 600025, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-8219","authenticated-orcid":true,"given":"R.","family":"Prakash","sequence":"additional","affiliation":[{"name":"Crescent School of Pharmacy, B.S.Abdur Rahman\nCrescent Institute of Science &amp; Technology-BSACIST University, Chennai, 600048, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Latha","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Technology,\nSree Padmavati MahilaVisvavidyalayam- Womens University, Tirupati, Andhra Pradesh, 517502, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/CIRCULATIONAHA.115.020380","volume":"133","author":"Wilson P.W.F.","year":"2016","unstructured":"Wilson P.W.F.; Changing cholesterol levels and coronary heart disease risk. Circulation 2016,133(3),239-241","journal-title":"Circulation"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrd1112","volume":"2","author":"Tobert J.A.","year":"2003","unstructured":"Tobert J.A.; Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003,2(7),517-526","journal-title":"Nat Rev Drug Discov"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"100012","DOI":"10.1016\/j.crphar.2020.100012","volume":"2","author":"Bhat A.","year":"2021","unstructured":"Bhat A.; Dalvi H.; Jain H.; Rangaraj N.; Singh S.B.; Srivastava S.; Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal. CRPHAR 2021,2,100012","journal-title":"CRPHAR"},{"key":"ref=4","first-page":"8","volume":"1","author":"Tjardo P.","year":"2017","unstructured":"Tjardo P.; Lyliana G.N.; Maya J.L.S.; Marc M.B.; Peter M.; Erna V.H.; Selene R.T.V.; Marieke J.H.B.; Iris E.C.S.; Statins as an adjuvant therapy for psychotic disorders: Current evidence with a systematic overview of double-blind placebo controlled trials. J Brain Dis 2017,1(1),8","journal-title":"J Brain Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1570159X15666170703101816","volume":"17","author":"Fracassi A.","year":"2018","unstructured":"Fracassi A.; Marangoni M.; Rosso P.; Pallottini V.; Fioramonti M.; Siteni S.; Segatto M.; Statins and the brain: More than lipid lowering agents? Curr Neuropharmacol 2018,17(1),59-83","journal-title":"Curr Neuropharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1089\/neu.2008.0554","volume":"25","author":"Tapia-Perez J.H.","year":"2008","unstructured":"Tapia-Perez J.H.; Sanchez-Aguilar M.; Torres-Corzo J.G.; Gordillo-Moscoso A.; Martinez-Perez P.; Madeville P.; de la Cruz-Mendoza E.; Chalita-Williams J.; Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J Neurotrauma 2008,25(8),1011-1017","journal-title":"J Neurotrauma"},{"key":"ref=7","first-page":"561","volume":"57","year":"2005","unstructured":"Stepie\u0144, K.; Tomaszewski, M.; Czuczwar, S.J. Neuroprotective properties of statins. Pharmacol Rep 2005,57(5),561-569","journal-title":"Pharmacol Rep"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1179\/1743132812Y.0000000080","volume":"34","author":"Shafaroodi H.","year":"2012","unstructured":"Shafaroodi H.; Moezi L.; Fakhrzad A.; Hassanipour M.; Rezayat M.; Dehpour A.R.; The involvement of nitric oxide in the anti-seizure effect of acute atorvastatin treatment in mice. Neurol Res 2012,34(9),847-853","journal-title":"Neurol Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eplepsyres.2010.07.021","volume":"91","author":"Candrilli S.D.","year":"2010","unstructured":"Candrilli S.D.; Manjunath R.; Davis K.L.; Gidal B.E.; The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy. Epilepsy Res 2010,91(2-3),260-266","journal-title":"Epilepsy Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1038\/s41598-020-58652-w","volume":"10","author":"Matsubara S.","year":"2020","unstructured":"Matsubara S.; Tanaka T.; Tomari S.; Fukuma K.; Ishiyama H.; Abe S.; Arimizu T.; Yamaguchi Y.; Ogata S.; Nishimura K.; Koga M.; Ando Y.; Toyoda K.; Ihara M.; Statin treatment can reduce incidence of early seizure in acute ischemic stroke: A propensity score analysis. Sci Rep 2020,10(1),1968","journal-title":"Sci Rep"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1517\/14656566.2012.713347","volume":"13","author":"Verrotti A.","year":"2012","unstructured":"Verrotti A.; Loiacono G.; Olivieri C.; Zulli E.; Zaccara G.; Lacosamide in patients with pharmacoresistant epilepsy. Expert Opin Pharmacother 2012,13(14),2065-2072","journal-title":"Expert Opin Pharmacother"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.jcbfm.9600265","volume":"26","author":"Stafstrom C.E.","year":"2006","unstructured":"Stafstrom C.E.; Epilepsy: A review of selected clinical syndromes and advances in basic science. J Cereb Blood Flow Metab 2006,26(8),983-1004","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"107464","DOI":"10.1016\/j.yebeh.2020.107464","volume":"113","author":"Wu T.","year":"2020","unstructured":"Wu T.; Chuang Y.C.; Huang H.C.; Lim S.N.; Hsieh P.F.; Lee W.T.; Cheng M.Y.; Tsai M.H.; Jou S.B.; Chang C.W.; Hsieh H.Y.; Du X.; Hellot S.; McClung C.; Hung C.; A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice. Epilepsy Behav 2020,113,107464","journal-title":"Epilepsy Behav"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7812\/TPP\/20.183","volume":"25","author":"Gurbani S.","year":"2021","unstructured":"Gurbani S.; Chayasirisobhon S.; Gurbani A.; Tovar S.; Pietzsch E.; Spurgeon B.; Effectiveness at 24 months of single-source generic carbamazepine, lamotrigine, or levetiracetam in newly diagnosed focal epilepsy. Perm J 2021,25(1),1-3","journal-title":"Perm J"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1111\/bcp.13626","volume":"84","author":"Lin H.W.","year":"2018","unstructured":"Lin H.W.; Ho Y.F.; Lin F.J.; Statin use associated with lower risk of epilepsy after intracranial haemorrhage: A population-based cohort study. Br J Clin Pharmacol 2018,84(9),1970-1979","journal-title":"Br J Clin Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.yebeh.2017.10.021","volume":"78","author":"Oliveira C.V.","year":"2018","unstructured":"Oliveira C.V.; Grigoletto J.; Canzian J.M.; Duarte M.M.M.F.; Duarte T.; Furian A.F.; Oliveira M.S.; Effect of atorvastatin on behavioral alterations and neuroinflammation during epileptogenesis. Epilepsy Behav 2018,78,109-117","journal-title":"Epilepsy Behav"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2174\/1389450116666150330114850","volume":"16","author":"Scicchitano F.","year":"2015","unstructured":"Scicchitano F.; Constanti A.; Citraro R.; Sarro G.; Russo E.; Statins and epilepsy: Preclinical studies, clinical trials and statin-anticonvulsant drug interactions. Curr Drug Targets 2015,16(7),747-756","journal-title":"Curr Drug Targets"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1136\/jnnp-2020-323524","volume":"91","author":"Vossler D.G.","year":"2020","unstructured":"Vossler D.G.; Knake S.; O\u2019Brien T.J.; Watanabe M.; Brock M.; Steiniger-Brach B.; Williams P.; Roebling R.; Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. J Neurol Neurosurg Psychiatry 2020,91(10),1067-1075","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1111\/epi.16366","volume":"60","author":"Lattanzi S.","year":"2019","unstructured":"Lattanzi S.; Trinka E.; Del Giovane C.; Nardone R.; Silvestrini M.; Brigo F.; Antiepileptic drug monotherapy for epilepsy in the elderly: A systematic review and network meta-analysis. Epilepsia 2019,60(11),2245-2254","journal-title":"Epilepsia"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"9861","DOI":"10.1073\/pnas.0308208101","volume":"101","author":"Lynch B.A.","year":"2004","unstructured":"Lynch B.A.; Lambeng N.; Nocka K.; Kensel-Hammes P.; Bajjalieh S.M.; Matagne A.; Fuks B.; The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci 2004,101(26),9861-9866","journal-title":"Proc Natl Acad Sci"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/ijp.IJP_261_16","volume":"49","author":"Gupta M.","year":"2017","unstructured":"Gupta M.; Levetiracetam-induced leukocytoclastic vasculitis. Indian J Pharmacol 2017,49(1),124-126","journal-title":"Indian J Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.seizure.2018.02.006","volume":"56","author":"Arican P.","year":"2018","unstructured":"Arican P.; Gencpinar P.; Cavusoglu D.; Olgac Dundar N.; Levetiracetam monotherapy for the treatment of infants with epilepsy. Seizure 2018,56,73-77","journal-title":"Seizure"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1755-5949.2010.00198.x","volume":"17","author":"Harris J.A.","year":"2011","unstructured":"Harris J.A.; Murphy J.A.; Lacosamide and Epilepsy. CNS Neurosci Ther 2011,17(6),678-682","journal-title":"CNS Neurosci Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/mol.107.039867","volume":"73","author":"Errington A.C.","year":"2008","unstructured":"Errington A.C.; St\u00f6hr T.; Heers C.; Lees G.; The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008,73(1),157-169","journal-title":"Mol Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","volume":"13","author":"Beyreuther B.K.","year":"2007","unstructured":"Beyreuther B.K.; Freitag J.; Heers C.; Krebsf\u00e4nger N.; Scharfenecker U.; St\u00f6hr T.; Lacosamide: A review of preclinical properties. CNS Drug Rev 2007,13(1),21-42","journal-title":"CNS Drug Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s12035-014-8775-9","volume":"51","author":"Wilson S.M.","year":"2015","unstructured":"Wilson S.M.; Khanna R.; Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: Implications for the therapeutic potential of lacosamide. Mol Neurobiol 2015,51(2),599-609","journal-title":"Mol Neurobiol"},{"key":"ref=27","first-page":"4","volume":"3","author":"Road J.C.","year":"1960","unstructured":"Road J.C.; A novel simple test for tranquilizing activity: The chimny test. MedicinaExperimentalis 1960,3,4","journal-title":"MedicinaExperimentalis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e23577","DOI":"10.1097\/MD.0000000000023577","volume":"99","author":"Zhao T.","year":"2020","unstructured":"Zhao T.; Ding Y.; Feng X.; Zhou C.; Lin W.; Effects of atorvastatin and aspirin on post-stroke epilepsy and usage of levetiracetam. Medicine 2020,99(50),e23577","journal-title":"Medicine"},{"key":"ref=29","first-page":"167","volume":"11","author":"Grados S.D.","year":"2019","unstructured":"Grados S.D.; Gracia G.A.; Garc\u00eda A.C.; Transient sinus dysfunction secondary to lacosamide treatment. CorSalud 2019,11(2),167-170","journal-title":"CorSalud"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/ana.21615","volume":"65","author":"Mintzer S.","year":"2009","unstructured":"Mintzer S.; Skidmore C.T.; Abidin C.J.; Morales M.C.; Chervoneva I.; Capuzzi D.M.; Sperling M.R.; Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009,65(4),448-456","journal-title":"Ann Neurol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.yebeh.2008.10.013","volume":"14","author":"Elliott J.O.","year":"2009","unstructured":"Elliott J.O.; Lu B.; Shneker B.; Charyton C.; Layne Moore J.; Comorbidity, health screening, and quality of life among persons with a history of epilepsy. Epilepsy Behav 2009,14(1),125-129","journal-title":"Epilepsy Behav"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"6446","DOI":"10.1074\/jbc.M807401200","volume":"284","author":"Miloushev V.Z.","year":"2009","unstructured":"Miloushev V.Z.; Levine J.A.; Arbing M.A.; Hunt J.F.; Pitt G.S.; Palmer A.G.; III Solution structure of the NaV1.2 C-terminal EF-hand domain. J Biol Chem 2009,284(10),6446-6454","journal-title":"J Biol Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.4103\/jnrp.jnrp_110_18","volume":"9","author":"Quintana-P\u00e1jaro L.D.J.","year":"2018","unstructured":"Quintana-P\u00e1jaro L.D.J.; Ramos-Villegas Y.; Cortecero-Sabalza E.; Joaquim A.F.; Agrawal A.; Narvaez-Rojas A.R.; Moscote-Salazar L.R.; The effect of statins in epilepsy: A systematic review. J Neurosci Rural Pract 2018,9(4),478-486","journal-title":"J Neurosci Rural Pract"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1177\/1060028018756650","volume":"52","author":"Trivedi L.U.","year":"2018","unstructured":"Trivedi L.U.; Alvarez C.A.; Mansi I.A.; Association of statin therapy with risk of epilepsy in 2 propensity score\u2013matched cohorts. Ann Pharmacother 2018,52(6),546-553","journal-title":"Ann Pharmacother"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"07004","DOI":"10.1051\/matecconf\/201819707004","volume":"197","author":"Permatananda P.A.N.K.K.","year":"2018","unstructured":"Permatananda P.A.N.K.K.; Adverse event of antiepileptic drugs: a cross sectional study. MATEC Web of Conferences 2018,197,07004","journal-title":"MATEC Web of Conferences"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.seizure.2015.07.001","volume":"31","author":"Zadeh W.W.","year":"2015","unstructured":"Zadeh W.W.; Escartin A.; Byrnes W.; Tennigkeit F.; Borghs S.; Li T.; Dedeken P.; De Backer M.; Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial. Seizure 2015,31,72-79","journal-title":"Seizure"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1517\/14740338.6.3.241","volume":"6","author":"Sirsi D.","year":"2007","unstructured":"Sirsi D.; Safdieh J.E.; The safety of levetiracetam. Expert Opin Drug Saf 2007,6(3),241-250","journal-title":"Expert Opin Drug Saf"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF02229077","volume":"16","author":"White H.S.","year":"1995","unstructured":"White H.S.; Johnson M.; Wolf H.H.; Kupferberg H.J.; The early identification of anticonvulsant activity: Role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. Ital J Neurol Sci 1995,16(1-2),73-77","journal-title":"Ital J Neurol Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2147\/NDT.S50371","volume":"10","author":"Kandratavicius L.","year":"2014","unstructured":"Kandratavicius L.; Balista P.; Lopes-Aguiar C.; Ruggiero R.; Umeoka E.; Garcia-Cairasco N.; Bueno-Junior L.; Leite J.; Animal models of epilepsy: Use and limitations. Neuropsychiatr Dis Treat 2014,10,1693-1705","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0920-1211(88)90054-X","volume":"2","author":"L\u00f6scher W.","year":"1988","unstructured":"L\u00f6scher W.; Schmidt D.; Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988,2(3),145-181","journal-title":"Epilepsy Res"},{"key":"ref=41","first-page":"363","volume":"55","author":"Swiader M.","year":"2003","unstructured":"Swiader M.; \u0141uszczki J.; Wielosz M.; Czuczwar S.J.; Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. Pol J Pharmacol 2003,55(3),363-370","journal-title":"Pol J Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1046\/j.1528-1157.2001.00003.x","volume":"42","author":"Klitgaard H.","year":"2001","unstructured":"Klitgaard H.; Levetiracetam: The preclinical profile of a new class of antiepileptic drugs? Epilepsia 2001,42(S4),13-18","journal-title":"Epilepsia"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/epi.16450","volume":"61","author":"Klein P.","year":"2020","unstructured":"Klein P.; Friedman A.; Hameed M.Q.; Kaminski R.M.; Bar-Klein G.; Klitgaard H.; Koepp M.; Jozwiak S.; Prince D.A.; Rotenberg A.; Twyman R.; Vezzani A.; Wong M.; L\u00f6scher W.; Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? Epilepsia 2020,61(3),359-386","journal-title":"Epilepsia"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"005","DOI":"10.17352\/aadc.000010","volume":"4","author":"Rajangam J","year":"2020","unstructured":"Rajangam J; Bhatt S; Krishnan N; Sammeta M; Joshna L; Infl fluence of metformin on learning and memory in experimental amnesia model in mice. Ann Alzheimers Dement Care 2020,4(1),005-009","journal-title":"Ann Alzheimers Dement Care"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.18034\/mjmbr.v4i1.426","volume":"4","author":"Rajangam J.","year":"2017","unstructured":"Rajangam J.; Manogna K.; Mounica K.; Padma C.; Swathi A.; Behavioural influence of Atorvastatin alone and in combination with antiepileptics against electroconvulsions in mice. Malays J Med Bio Res 2017,4(1),63-70","journal-title":"Malays J Med Bio Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/1871524920999200831153214","volume":"20","author":"Sahu D.R.","year":"2021","unstructured":"Sahu D.R.; Chowdhury B.; Sahoo B.M.; Anti-convulsant action and attenuation of oxidative stress by citrus limon peel extracts in PTZ and MES induced convulsion in Albino rats. Cent Nerv Syst Agents Med Chem 2021,20(3),177-185","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"ref=47","first-page":"1","volume":"18","author":"Jayaraman R.","year":"2018","unstructured":"Jayaraman R.; Lavanya O.; Effect of rosuvastatin on learning and memory in scopolamine induced amnesia in Mice. Trends in Medicine 2018,18,1-4","journal-title":"Trends in Medicine"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"S328","DOI":"10.1016\/j.jscs.2012.12.005","volume":"20","author":"Sangshetti J.N.","year":"2016","unstructured":"Sangshetti J.N.; Aqeel M.; Zaheer Z.; Ahmed R.Z.; Dehghan M.H.G.; Gonjari I.; Development and validation of RP-HPLC method for determination of Atorvastatin calcium and Nicotinic acid in combined tablet dosage form. J Saudi Chem Soc 2016,20,S328-S333","journal-title":"J Saudi Chem Soc"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.jpba.2006.02.010","volume":"41","author":"Siewert S.","year":"2006","unstructured":"Siewert S.; Validation of a levofloxacin HPLC assay in plasma and dialysate for pharmacokinetic studies. J Pharm Biomed Anal 2006,41(4),1360-1362","journal-title":"J Pharm Biomed Anal"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"104632","DOI":"10.1016\/j.jbc.2023.104632","volume":"299","author":"Franchi F.","year":"2023","unstructured":"Franchi F.; Marte A.; Corradi B.; Sterlini B.; Alberini G.; Romei A.; De Fusco A.; Vogel A.; Maragliano L.; Baldelli P.; Corradi A.; Valente P.; Benfenati F.; The intramembrane COOH-terminal domain of PRRT2 regulates voltage-dependent Na+ channels. J Biol Chem Epub ahead of print2023,299(5),104632","journal-title":"J Biol Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.30476\/IJMS.2021.91645.2289","volume":"48","author":"Amanlou A.","year":"2023","unstructured":"Amanlou A.; Nassireslami E.; Dehpour A.R.; Rashidian A.; Chamanara M.; Beneficial effects of statins on seizures independent of their lipid-lowering effect: A narrative review. Iran J Med Sci 2023,48(1),13-25","journal-title":"Iran J Med Sci"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"249","DOI":"10.31024\/ajpp.2019.5.2.5","volume":"5","author":"Rizaldy T.P.","year":"2019","unstructured":"Rizaldy T.P.; Fransiscus B.; Rosa De L.R.S.; Andre D.J.; Antiepileptic drugs and quality of life in patients with epilepsy: A tertiary care hospitalbased study. Asian J Pharm Pharmacol 2019,5(2),249-254","journal-title":"Asian J Pharm Pharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","volume":"52","author":"Biton V","year":"2015","unstructured":"Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB; Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav 2015,52(Pt A),119-727","journal-title":"Epilepsy Behav"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1517\/14740338.3.5.415","volume":"3","author":"Briggs D.E.","year":"2004","unstructured":"Briggs D.E.; French J.A.; Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf 2004,3(5),415-424","journal-title":"Expert Opin Drug Saf"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.1002\/0471141755.ph0522s45","author":"Giardina W.J.","year":"2009","unstructured":"Giardina W.J.; Gasior M.;  Acute seizure tests in epilepsy research: Electroshock- and chemical-induced convulsions in the mouse 2009","journal-title":"Acute seizure tests in epilepsy research: Electroshock- and chemical-induced convulsions in the mouse"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/nan.12451","volume":"44","author":"Becker A.J.","year":"2018","unstructured":"Becker A.J.; Review: Animal models of acquired epilepsy: Insights into mechanisms of human epileptogenesis. Neuropathol Appl Neurobiol 2018,44(1),112-129","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eplepsyres.2005.09.012","volume":"68","author":"Rogawski M.A.","year":"2006","unstructured":"Rogawski M.A.; Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res 2006,68(1),22-28","journal-title":"Epilepsy Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","volume":"353","author":"Klitgaard H.","year":"1998","unstructured":"Klitgaard H.; Matagne A.; Gobert J.; W\u00fclfert E.; Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998,353(2-3),191-206","journal-title":"Eur J Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/bjp.2008.198","volume":"154","author":"Matagne A.","year":"2008","unstructured":"Matagne A.; Margineanu D-G.; Kenda B.; Michel P.; Klitgaard H.; Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008,154(8),1662-1671","journal-title":"Br J Pharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1211\/jpp.62.05.0008","volume":"62","author":"Jayaraman R.","year":"2010","unstructured":"Jayaraman R.; Manisenthil K.T.; Anitha T.; Joshi V.D.; Palei N.N.; Gajera K.; Ladani K.; Influence of etoricoxib on anticonvulsant activity of phenytoin and diazepam in experimental seizure models in mice. J Pharm Pharmacol 2010,62(5),610-614","journal-title":"J Pharm Pharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1528-1167.2008.01713.x","volume":"50","author":"Kaminski R.M.","year":"2009","unstructured":"Kaminski R.M.; Matagne A.; Patsalos P.N.; Klitgaard H.; Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam. Epilepsia 2009,50(3),387-397","journal-title":"Epilepsia"},{"key":"ref=62","first-page":"27","author":"Hardman J.GLL.","year":"2010","unstructured":"Hardman J.GLL.; Goodman A.;  Drugs effective in the therapy of the epilepsies 2010,27","journal-title":"Drugs effective in the therapy of the epilepsies"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ana.410200202","volume":"20","author":"Yaari Y.","year":"1986","unstructured":"Yaari Y.; Selzer M.E.; Pincus J.H.; Phenytoin: Mechanisms of its anticonvulsant action. Ann Neurol 1986,20(2),171-184","journal-title":"Ann Neurol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2217\/thy.11.19","volume":"8","author":"Cook A.M.","year":"2011","unstructured":"Cook A.M.; Bensalem-Owen M.K.; Mechanisms of action of antiepileptic drugs. Therapy 2011,8(3),307-313","journal-title":"Therapy"},{"key":"ref=65","first-page":"37","year":"1911","unstructured":"W S. A sensitive biological response to morphine. Dtsch Med Wochenschr 1911,37","journal-title":"Dtsch Med Wochenschr"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1476-5381.1960.tb00277.x","volume":"15","author":"Bilbey D.L.J.","year":"1960","unstructured":"Bilbey D.L.J.; Salem H.; Grossman M.H.; The anatomical basis of the straub phenomenon. Br J Pharmacol Chemother 1960,15(4),540-543","journal-title":"Br J Pharmacol Chemother"},{"key":"ref=67","author":"Orrin Devinsky J.I.S.","year":"2014","unstructured":"Orrin Devinsky J.I.S.;  Myoclonic Seizures Available from:2014","journal-title":"Myoclonic Seizures"},{"key":"ref=68","first-page":"43","author":"Ruth A.","year":"2011","unstructured":"Ruth A.; Medications, Herbal Preparations, and Natural Products in Breast Milk; Ruth, A.; Lawrence, RML, Eds.; W.B. Saunders 2011,43"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1111\/j.1528-1157.1986.tb05735.x","volume":"27","author":"Lesser R.P.","year":"1986","unstructured":"Lesser R.P.; L\u00fcders H.; Wyllie E.; Dinner D.S.; Iii H.H.M.; Mental deterioration in epilepsy. Epilepsia 1986,27(S2),S105-S123","journal-title":"Epilepsia"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.yebeh.2012.02.001","volume":"23","author":"Moezi L.","year":"2012","unstructured":"Moezi L.; Shafaroodi H.; Hassanipour M.; Fakhrzad A.; Hassanpour S.; Dehpour A.R.; Chronic administration of atorvastatin induced anti-convulsant effects in mice: The role of nitric oxide. Epilepsy Behav 2012,23(4),399-404","journal-title":"Epilepsy Behav"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0091-3057(95)02126-4","volume":"54","author":"Hogg S.","year":"1996","unstructured":"Hogg S.; A review of the validity and variability of the Elevated Plus-Maze as an animal model of anxiety. Pharmacol Biochem Behav 1996,54(1),21-30","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF02253713","volume":"101","author":"Itoh J.","year":"1990","unstructured":"Itoh J.; Nabeshima T.; Kameyama T.; Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology 1990,101(1),27-33","journal-title":"Psychopharmacology"},{"key":"ref=73","first-page":"e2609","author":"Deacon R.M.","year":"2013","unstructured":"Deacon R.M.; Measuring motor coordination in mice. J Vis Exp 2013(75),e2609","journal-title":"J Vis Exp"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1001\/archneur.59.12.1909","volume":"59","author":"Sohn Y.H.","year":"2002","unstructured":"Sohn Y.H.; Jung H.Y.; Kaelin-Lang A.; Hallett M.; Effect of levetiracetam on rapid motor learning in humans. Arch Neurol 2002,59(12),1909-1912","journal-title":"Arch Neurol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.seizure.2013.05.010","volume":"22","author":"Lang N.","year":"2013","unstructured":"Lang N.; Rothkegel H.; Peckolt H.; Deuschl G.; Effects of lacosamide and carbamazepine on human motor cortex excitability: A double-blind, placebo-controlled transcranial magnetic stimulation study. Seizure 2013,22(9),726-730","journal-title":"Seizure"},{"key":"ref=76","first-page":"5","volume":"05","author":"Nayak V.A.S.","year":"2013","unstructured":"Nayak V.A.S.; Poornima B.M.; Sharma R.; Garg A.; Shetty M.; Kamath S.; Hegde M.; Koshy S.S.; Effect of chronic administration of atorvastatin, simvastatin and lovastatin on animal models of epilepsy. Int J Curr Res Rev 2013,05(19),5","journal-title":"Int J Curr Res Rev"},{"key":"ref=77","first-page":"4","volume":"6","author":"Ashwini P.R.M.S.","year":"2017","unstructured":"Ashwini P.R.M.S.; Potential anti-seizure activity of atorvastatin in rat models of seizure. Int J Basic Clin Pharmacol 2017,6(1),4","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref=78","first-page":"44","volume":"1","author":"Mohammad J.K.","year":"2015","unstructured":"Mohammad J.K.; Nader T.; Samaneh N.; Anticonvulsant activity of atorvastatin against seizure induced by pentylenetetrazole and maximal electroshock in mice trends in pharmaceutical sciences. Trends Pharmacol Sci 2015,1(1),44-47","journal-title":"Trends Pharmacol Sci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1067\/mcp.2000.110537","volume":"68","author":"Mazzu A.","year":"2000","unstructured":"Mazzu A.; Lasseter K.C.; Shamblen E.C.; Agarwal V.; Lettieri J.; Sundaresen P.; Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000,68(4),391-400","journal-title":"Clin Pharmacol Ther"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clpt.2005.04.007","volume":"78","author":"Backman J.","year":"2005","unstructured":"Backman J.; Luurila H.; Neuvonen M.; Neuvonen P.; Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005,78(2),154-167","journal-title":"Clin Pharmacol Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"71","DOI":"10.7326\/L19-0712","volume":"173","author":"Paciullo F.","year":"2020","unstructured":"Paciullo F.; Costa C.; Gresele P.; Rivaroxaban plasma levels and levetiracetam: A case report. Ann Intern Med 2020,173(1),71-72","journal-title":"Ann Intern Med"},{"key":"ref=82","first-page":"P01.076","volume":"78","author":"Cawello W","year":"2020","unstructured":"Cawello W; Surmann E; Waitzinger J.; Lacosamide has no effect on the enzymatic activity of CYP3A4 (P01.076). Neurology 2020,78(S1),P01.076","journal-title":"Neurology"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002253895231020100743","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/222705\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002253895231020100743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T12:47:43Z","timestamp":1704286063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/222705\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":82,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892002253895231020100743","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}